RU2004125594A - Применение тиболона при лечение симптомов, связанных с введением лекарств, препятствующих синтезу эндогенного эстрогена - Google Patents

Применение тиболона при лечение симптомов, связанных с введением лекарств, препятствующих синтезу эндогенного эстрогена Download PDF

Info

Publication number
RU2004125594A
RU2004125594A RU2004125594/14A RU2004125594A RU2004125594A RU 2004125594 A RU2004125594 A RU 2004125594A RU 2004125594/14 A RU2004125594/14 A RU 2004125594/14A RU 2004125594 A RU2004125594 A RU 2004125594A RU 2004125594 A RU2004125594 A RU 2004125594A
Authority
RU
Russia
Prior art keywords
symptoms
estrogen
synthesis
treatment
endogenous estrogen
Prior art date
Application number
RU2004125594/14A
Other languages
English (en)
Russian (ru)
Inventor
Хелениус Ян КЛОСТЕРБУР (NL)
Хелениус Ян КЛОСТЕРБУР
Найджел БУНДРЕД (GB)
Найджел БУНДРЕД
Original Assignee
Акцо Нобель Н.В. (NL)
Акцо Нобель Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Акцо Нобель Н.В. (NL), Акцо Нобель Н.В. filed Critical Акцо Нобель Н.В. (NL)
Publication of RU2004125594A publication Critical patent/RU2004125594A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
RU2004125594/14A 2002-01-22 2003-01-16 Применение тиболона при лечение симптомов, связанных с введением лекарств, препятствующих синтезу эндогенного эстрогена RU2004125594A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02075235 2002-01-22
EP02075235.8 2002-01-22

Publications (1)

Publication Number Publication Date
RU2004125594A true RU2004125594A (ru) 2005-03-10

Family

ID=27589110

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2004125594/14A RU2004125594A (ru) 2002-01-22 2003-01-16 Применение тиболона при лечение симптомов, связанных с введением лекарств, препятствующих синтезу эндогенного эстрогена

Country Status (16)

Country Link
US (1) US20050124592A1 (enExample)
EP (1) EP1469861A1 (enExample)
JP (1) JP2005518412A (enExample)
KR (1) KR20040073572A (enExample)
CN (1) CN1620298A (enExample)
BR (1) BR0306789A (enExample)
CA (1) CA2472240A1 (enExample)
EC (1) ECSP045179A (enExample)
HR (1) HRP20040635A2 (enExample)
IL (1) IL162769A0 (enExample)
IS (1) IS7338A (enExample)
MX (1) MXPA04007071A (enExample)
PL (1) PL371181A1 (enExample)
RU (1) RU2004125594A (enExample)
WO (1) WO2003061665A1 (enExample)
ZA (1) ZA200405262B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302572D0 (en) 2003-02-05 2003-03-12 Astrazeneca Ab Method of treatment

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE63051B1 (en) * 1989-03-18 1995-03-22 Akzo Nv Pharmaceutical composition which contains a pharmaceutically suitable carrier and the compound having the structure (7alpha, 17alpha)-17-Hydroxy-7-methyl-19-nor-17-pregn-5(10)-en-20-yn- 3-one
AU671706B2 (en) * 1993-03-05 1996-09-05 Akzo N.V. Use of a Pregnane Derivative
JP2002522425A (ja) * 1998-08-07 2002-07-23 カイロン コーポレイション エストロゲンレセプターモジュレーターとしての置換イソオキサゾール

Also Published As

Publication number Publication date
JP2005518412A (ja) 2005-06-23
IS7338A (is) 2004-06-28
IL162769A0 (en) 2005-11-20
CN1620298A (zh) 2005-05-25
WO2003061665A1 (en) 2003-07-31
EP1469861A1 (en) 2004-10-27
US20050124592A1 (en) 2005-06-09
BR0306789A (pt) 2004-12-28
CA2472240A1 (en) 2003-07-31
ECSP045179A (es) 2004-08-27
ZA200405262B (en) 2005-08-31
PL371181A1 (en) 2005-06-13
KR20040073572A (ko) 2004-08-19
HRP20040635A2 (en) 2004-10-31
MXPA04007071A (es) 2004-10-29

Similar Documents

Publication Publication Date Title
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
BR0212078A (pt) Método de tratar ou prevenir uma doença relacionada com amilóide em um paciente, composição farmacêutica, composto quìmico, e, uso de um composto
US20020013300A1 (en) Methods for improving size and appearance of a wound
DE60316779D1 (de) Thiadiazolylpiperazinderivate geeignet für die behandlung bzw. prävention von schmerzen
BR0115109A (pt) Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese
JP2001510795A5 (enExample)
KR970061244A (ko) 치매 치료용 약학 조성물
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
JP2004537500A5 (enExample)
JP2021502392A5 (enExample)
JP2003528919A5 (enExample)
RU2007101695A (ru) Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
WO2005094899A8 (en) Clusterin antisense therapy for treatment of cancer
PE20031047A1 (es) Tratamiento de padecimientos post-menopausicos en pacientes con cancer de mama
HUP0101005A2 (hu) Szteroid aromatáz gátlót tartalmazó gyógyszer emlőrák megelőzésére és/vagy kezelésére
RU2004125594A (ru) Применение тиболона при лечение симптомов, связанных с введением лекарств, препятствующих синтезу эндогенного эстрогена
US6245812B1 (en) Treatment of hot flashes (flushing) using leucine alone or in combination with other branched chain amino acids
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
HUP0500896A2 (en) Composition of estrogen and other hormones with ascorbate, lysine, proline and other substances
RU2002129298A (ru) Применение галантамина для лечения психоневрологического поведения, связанного с болезнью альцгеймера
MXPA03009446A (es) Inhibicion de aromatasa para mejorar reproduccion asistida.
JP2004529924A5 (enExample)
CA2444980A1 (en) Single dose aromatase inhibitor for treating infertility
RU99116652A (ru) Способ лечения злокачественной лимфомы кожи
JP2005518412A5 (enExample)

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20060719